COMPARE · Reviewed August 3, 2026
COR vs HSIC
Verdict: Side-by-side breakdown using the Bull Rankings model. COR scored 65.7, HSIC scored 52.9 — COR leads.
Compare another set
COR
Cencora, Inc.
65.7
$305.19 · $59.4B
fundamentals as of
Score gap
12.8
COR leads
HSIC
Henry Schein, Inc.
52.9
$88.33 · $10.1B
fundamentals as of
The model, pillar by pillar (0–100 each)
COR
stronger →← stronger
HSIC
64
Qualityreturns · margins · balance sheet
61
76
Growthrevenue & earnings expansion
68
59
Valuevaluation vs sector peers
35
COR is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
COR
HSIC
$1.6bC+
FCF
$445mC
+5.9%C+
Rev
+5.6%C+
4.21D
D/E
0.78C+
23.4xB+
P/E
26.7xB
0.66A-
PEG
1.84C+
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
COR
HSIC
42% above
Price vs fair valuelower is cheaper
10% above
~16%/yr
Growth the price implies10-yr FCF · lower = less priced in
~9%/yr
-37%
1-yr DCF upside
-18%
-30%
5-yr DCF upside
-9%
-17%
10-yr DCF upside
+5%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
COR
Why this score
- Raising its dividend
- Durable high returns
HSIC
Why this score
- Buying back stock
The companies
CORCencora, Inc.
Why now
Medical Distribution · market cap $59.4b. 19% off the 52-week high of $377.54. PEG 0.66 — paying under fair value for the growth rate. 12 sell-side analysts rate this a Buy with a mean 1-yr target of $356.67 (implying +17% upside).
Moat
ROE 75% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $59.4b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk
D/E 4.21 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Net margin 0.8% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
HSICHenry Schein, Inc.
Why now
Medical Distribution · market cap $10.1b. 4% off the 52-week high of $92.17. 16 sell-side analysts rate this a Buy with a mean 1-yr target of $89.31 (implying +1% upside).
Moat
ROE 13% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 107% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Net margin 3.1% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.